多中心碳离子放疗治疗口咽非鳞状细胞癌的研究。
Multicenter Study of Carbon-ion Radiotherapy for Oropharyngeal Non-squamous Cell Carcinoma.
机构信息
Ion Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan.
QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.
出版信息
In Vivo. 2021 Jul-Aug;35(4):2239-2245. doi: 10.21873/invivo.12496.
BACKGROUND/AIM: To evaluate treatment outcomes of carbon-ion radiotherapy for oropharyngeal non-squamous cell carcinoma at four carbon-ion facilities in Japan.
PATIENTS AND METHODS
We retrospectively analyzed the cases of 33 patients with oropharyngeal non-squamous cell carcinoma who were treated with carbon-ion radiotherapy between November 2003 and December 2014.
RESULTS
The histology included adenoid cystic carcinoma (n=25) and mucosal malignant melanoma (n=4). No patients had T1 tumors; 23 had T4 tumors. The most-commonly prescribed dose was 57.6 Gy (RBE) in 16 fractions. The median follow-up period was 34.8 months (range=4.2-122.8 months). The 3-year local control and overall survival rates were 94.7% and 90.7%, respectively. There were no grade ≥4 acute adverse events. Only one patient experienced a grade ≥4 late adverse event. No patients experienced late adverse events related to swallowing or salivary function.
CONCLUSION
Carbon-ion radiotherapy appears to be a promising treatment option for oropharyngeal non-squamous cell carcinoma.
背景/目的：评估日本四家重离子设施治疗口咽非鳞状细胞癌的治疗效果。
患者与方法
我们回顾性分析了 2003 年 11 月至 2014 年 12 月期间接受重离子放疗的 33 例口咽非鳞状细胞癌患者的病例。
结果
组织学包括腺样囊性癌（n=25）和黏膜恶性黑色素瘤（n=4）。没有 T1 期肿瘤患者；23 例 T4 期肿瘤患者。最常规定剂量为 57.6Gy（RBE），共 16 次。中位随访时间为 34.8 个月（范围 4.2-122.8 个月）。3 年局部控制率和总生存率分别为 94.7%和 90.7%。无≥4 级急性不良反应。仅有 1 例患者发生≥4 级迟发性不良反应。无患者出现与吞咽或唾液功能相关的迟发性不良反应。
结论
重离子放疗似乎是口咽非鳞状细胞癌的一种有前途的治疗选择。
Zotero 插件